Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Ventas

Ominous Death Cross Forms On Ventas's Chart

If history is any guide, there may be trouble ahead for shares of Ventas (NYSE:VTR). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Expert Ratings for Ventas

Expert Ratings for Ventas

Ventas (NYSE:VTR) has observed the following analyst ratings within the last quarter:

Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2022

Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2022

Where Ventas Stands With Analysts

Within the last quarter, Ventas (NYSE:VTR) has observed the following analyst ratings:

Golden Cross Appears Before Ventas Investors

If history is any guide, there may be good fortune ahead for shares of Ventas (NYSE:VTR). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much

Ventas (NYSE:VTR) has outperformed the market over the past 20 years by 1.04% on an annualized basis producing an average annual return of 8.02%. Currently, Ventas has a market capitalization of $23.65 billion.

inkl

Read news from The Economist, FT, and more,
with one subscription

Where Ventas Stands With Analysts

Where Ventas Stands With Analysts

Within the last quarter, Ventas (NYSE:VTR) has observed the following analyst ratings:

Ventas: Debt Overview

Ventas: Debt Overview

Shares of Ventas (NYSE:VTR) fell by 2.51% in the past three months. Before having a look at the importance of debt, let us look at how much debt Ventas has.

What 4 Analyst Ratings Have To Say About Ventas

What 4 Analyst Ratings Have To Say About Ventas

Within the last quarter, Ventas (NYSE:VTR) has observed the following analyst ratings:

Organisations

Advanced Micro Devices

Cardinal Health

Monster Beverage

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play